Yahoo Finance11d
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
Xeris also announced it has partnered with American Regent to commercialize Gvoke VialDx. Under the terms of the agreement, ...
MPR3d
FDA Approves Gvoke VialDx to Inhibit GI Motility During Diagnostic Procedures
Gvoke VialDx is a concentrated liquid glucagon product. For diagnostic procedures, it works as a gastrointestinal motility inhibitor. The product is supplied as a single-dose vial containing 1mg of ...
Crain's Chicago Business9d
Xeris enters a whole new market for one of its main pharma offerings
Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal ...
Morningstar11d
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
Xeris also announced it has partnered with American Regent to commercialize Gvoke VialDx. Under the terms of the agreement, Xeris will be responsible for product supply, and American Regent will ...
FDA approves Xeris Biopharma’s sNDA of Gvoke VialDx as gastro diagnostic aid
Holdings announced that its supplemental new drug application, sNDA, of Gvoke VialDx has received U.S Food and Drug ...
Investing11d
Xeris Biopharma gets FDA nod for Gvoke VialDx, teams with American Regent
InvestingPro analysis reveals 8 additional key insights about the company’s potential. Gvoke VialDx™ is designed to temporarily inhibit gastrointestinal movement during diagnostic procedures ...
Investing11d
Xeris Biopharma gets FDA nod for Gvoke VialDx, teams with American Regent
CHICAGO - Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a $742 million market cap pharmaceutical company whose stock has surged 116% over the past year, has announced the FDA approval of its ...